Optimistic Outlook for IN8bio: A Buy Rating Ahead of Key Data Release

TipRanksMay 1 00:15

IN8bio Doses First Patient In Phase 2 Clinical Trial Of INB-400 In Newly Diagnosed Glioblastoma

IN8bio Doses First Patient In Phase 2 Clinical Trial Of INB-400 In Newly Diagnosed Glioblastoma

BenzingaApr 30 18:07

IN8bio Announces Oral Presentation at the Upcoming American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting

NEW YORK, April 24, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB) a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced an oral presen

In8bioApr 24 12:00

IN8bio to Present at Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference

NEW YORK, April 16, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB) a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced that William H

In8bioApr 16 12:00

12 Health Care Stocks Moving In Friday's After-Market Session

GainersQilian Intl Hldg Gr (NASDAQ:QLI) stock moved upwards by 50.4% to $1.14 during Friday's after-market session. The company's market cap stands at $40.7 million. Allarity Therapeutics (NASDAQ:ALLR

BenzingaApr 13 04:31

Promising Preclinical Data Underpins Buy Rating for IN8bio's NsCAR Platform

TipRanksApr 12 13:45